Drug intelligence / Profile preview

Neu-REFIX beta glucan

Development stage
Preclinical
Lead developer
GN Corporation
Modality
Microbiome-Derived Products → Microbiome Therapeutics
Administration
Oral
01

Overview

Neu-REFIX beta glucan is an orally consumable, allergen-free food supplement in gel form, developed by GN Corporation in Japan. The active ingredient is a beta-1,3-1,6-glucan exo-polysaccharide produced by the N-163 strain of *Aureobasidium pullulans* yeast. It functions as a biological response modifier glucan (BRMG), acting as a pathogen-associated molecular pattern (PAMP) to trigger immune responses through pattern recognition receptors like Dectin-1 and complement receptor 3 (CR3). [4] It is primarily being investigated for Duchenne muscular dystrophy (DMD), where it has demonstrated anti-inflammatory, anti-fibrotic, and muscle regeneration properties in preclinical models and clinical studies. [1, 2] The product has received Rare Pediatric Disease and Orphan Drug Designations from the US FDA for DMD. [1, 7, 10] Research has also explored its potential in other conditions, including multiple sclerosis, non-alcoholic steatohepatitis (NASH), COVID-19, and psoriasis vulgaris. [4, 11, 12] It has been commercially available in Japan as a food supplement since 2018. [1, 8]

Brand names
Neu-REFIXneu REFIX
Other names
Aureobasidium pullulans N-163 beta-glucanN-163 beta-glucanN163 beta-glucanN 163 beta-glucan
02

Targets

CLEC7A (Dectin-1)αMβ2 (Integrin αMβ2)

Beyond the preview

Go deeper on Neu-REFIX beta glucan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neu-REFIX beta glucan.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call